Samsung Biologics Q1 Revenue Jumps 25.7%

Samsung Biologics posted Q1 revenue of 1,257 bn won, up 25.7% YoY, beating estimates of 1,266 bn won.
Net profit rose 41.7% to 469 bn won, surpassing consensus of 455 bn won, with margin improving to 37.3%.
Shares slipped 3% after the release, while management reaffirmed FY2026 revenue growth target of 15‑20% and mid‑40% operating margin.
Revenue remained flat versus Q4 2025 at 1,286 bn won, reflecting full utilization of Plants 1‑4 and some deferred Q4 revenue.